

# Visiting Professors

## A case-based discussion on the management of prostate cancer

### Select Publications

- ALSYMPCA: A double-blind, randomised, multiple dose, Phase III, multicentre study of Alpharadin in the treatment of patients with symptomatic hormone refractory prostate cancer with skeletal metastases. **NCT00699751**
- Cathomas R et al. **Cetuximab in combination with docetaxel in patients (pts) with metastatic castration resistant (mCRPC) and docetaxel-refractory prostate cancer: A multicenter phase II trial (SAKK 08/07).** *Proc ASCO* 2010;Abstract 4666.
- De Bono JS et al. **Abiraterone and increased survival in metastatic prostate cancer.** *N Engl J Med* 2011;364(21):1995-2005.
- De Bono JS et al. **Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: A randomised open-label trial.** *Lancet* 2010;376(9747):1147-54.
- FIRSTANA: Randomized, open label, multi-center study comparing cabazitaxel at 25 mg/m<sup>2</sup> and at 20 mg/m<sup>2</sup> in combination with prednisone every 3 weeks to docetaxel in combination with prednisone in patients with metastatic castration resistant prostate cancer not pretreated with chemotherapy. **NCT01308567**
- Fizazi K et al. **Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: A randomised, double-blind study.** *Lancet* 2011;377(9768):813-22.
- Fizazi K et al. **A randomized phase III trial of denosumab versus zoledronic acid in patients with bone metastases from castration-resistant prostate cancer.** *Proc ASCO* 2010;Abstract LBA4507.
- Fusco V et al. **Osteonecrosis of the jaw after zoledronic acid and denosumab treatment.** *J Clin Oncol* 2011;29(17):e521-2.
- Galsky MD, Vogelzang NJ. **Docetaxel-based combination therapy for castration-resistant prostate cancer.** *Ann Oncol* 2010;21(11):2135-44.
- Hussain M et al. **Cabozantinib (XL184) in metastatic castration-resistant prostate cancer (mCRPC): Results from a phase II randomized discontinuation trial.** *Proc ASCO* 2011;Abstract 4516.
- Kantoff PW et al. **Sipuleucel-T immunotherapy for castration-resistant prostate cancer.** *N Engl J Med* 2010;363(5):411-22.
- Mainsail: A Phase 3 study to evaluate the efficacy and safety of docetaxel and prednisone with or without lenalidomide in subjects with castrate-resistant prostate cancer. **NCT00988208**
- Miller K et al. **Benefit of denosumab therapy in patients with bone metastases from castrate resistant prostate cancer: A number-needed-to-treat (NNT) analysis.** *Proc AUA* 2011;Abstract 648.
- Nilsson S et al. **Alpharadin, a novel, highly targeted alpha pharmaceutical with a good safety profile for patients with CRPC and bone metastases: Combined analyses of phase I and II clinical trials.** GU Cancers Symposium 2010;Abstract 106.
- Ozgunoglu M et al. **Impact of G-CSF prophylaxis on the occurrence of neutropenia in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving cabazitaxel.** *Proc ASCO* 2011;Abstract e15131.
- Sartor AO. **Progression of metastatic castrate-resistant prostate cancer: Impact of therapeutic intervention in the post-docetaxel space.** *J Hematol Oncol* 2011;4:18.
- Smith MR et al. **Denosumab in men receiving androgen-deprivation therapy for prostate cancer.** *N Engl J Med* 2009;361(8):745-55.